Den svenska life science-industrins utveckling - Tillväxtanalys

Projektengagemang: Leaving 2019 behind - SEB - Börskollen

EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden EnginZyme is a biotechnology company that specializes in biocatalysis. EnginZyme erweitert Serie-A-Finanzierung auf 11 Mio. Euro, um seine zellfreie Chemieproduktionsplattform voranzubringen – Finanzierungsrunde geführt vom schwedischen Investor Industrifonden EnginZyme is seeking a Chief Financial Officer to lead the company's financial operations and funding strategy. EnginZyme is a Swedish startup founded in 2014 that has developed a platform for sustainably producing both the current building blocks of the world — the billion tonnes of plastics, nylons, rubbers, and all the other things that we touch on a day-to-day basis — as well as The extension round was led by Industrifonden followed by SEB Greentech VC and existing shareholders. “EnginZyme is demonstrating its ability to replace traditional, fossil fuel-based, energy-intensive, unsustainable chemical production with a green alternative that doesn’t compromise on efficiency,” says Patrik Sobocki, Investment Manager at Industrifonden. EnginZyme utökar Serie A-runda till 111 MSEK för att vidareutveckla bioteknologisk produktionsplattform i finansiering ledd av Industrifonden 02/11/2021 - 01:00 AM STOCKHOLM--( Huvudägare: Grundarna och vd, Industrifonden, Chalmers Ventures. År på 33-listan: 2020. Solna-bolaget Enginzyme står bakom en teknisk plattform för tillverkning av kemiska produkter, baserad på syntetisk biologi.

Based in Sweden, we have a reach across the Nordics. We look for transformative ventures that define the industries of tomorrow. Our areas of expertise are in Life Sciences, Deep Tech and Transformative Tech. Den statligt grundade stiftelsen Industrifonden ledde en finansieringsrunda i Enginzyme, som utvecklar en teknisk plattform för hållbar produktion av kemikalier. Det framgår av ett pressmeddelande.

All about DR - Zip.news

2021-02-11 Industrifonden has led a €4.6m series-A extension for Stockholm-based biotech startup EnginZyme., Early-stage, Nordics, Technology, Sweden, Sofinnova Partners, Industrifonden, Nordic venture - #private-equity #HedgeMaven February 11, 2021 01:00 AM Eastern Standard Time STOCKHOLM--(BUSINESS WIRE)--EnginZyme, a company developing a technology platform for sustainable production of chemicals, today announced it has closed an extension to its Series A financing round, bringing the total raised to €11 million.The extension round was led by Industrifonden, Sweden’s largest deep tech venture capital firm EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden EnginZyme seeks to transform the $5 trillion chemical industry through the use of its enzyme-based platform, which combines the breadth and power of nature with the efficiencies of state-of-the-art chemical processing techniques "EnginZyme is demonstrating its ability to replace traditional, fossil fuel-based, energy-intensive, unsustainable chemical production with a green alternative that doesn’t compromise on efficiency," said Patrik Sobocki, Investment Manager at Industrifonden. EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden EnginZyme, a company developing a technology platform for sustainable production of chemicals, today announced it has closed an extension to its Series A financing round, bringing the total raised to €11 million. Den statligt grundade stiftelsen Industrifonden ledde en finansieringsrunda i Enginzyme, som utvecklar en teknisk plattform för hållbar produktion av kemikalier.

Nu ska svenska kemistens uppfinning revolutionera marknaden

February 17, 2021. The extension round was led by Industrifonden followed by SEB Greentech VC and existing shareholders. “EnginZyme is demonstrating its ability to replace traditional, fossil fuel-based, energy-intensive, Athera (company). Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases. EnginZyme utökar Serie A-runda till 111 MSEK för att vidareutveckla bioteknologisk produktionsplattform i finansiering ledd av Industrifonden 02/11/2021 - 01:00 AM STOCKHOLM--( EnginZyme utvecklar en ny teknikplattform för konstruktion och driftsättning av biologiska fabriker baserade på enzymer för produktion av kemikalier.

The Stockholm-based company has just raised an €11m Series A extension round from Industrifonden, the Swedish government-backed VC, in order to get the technology out of the lab and into manufacturing companies. 2021-02-11 · EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden's Industrifonden EnginZyme, a company developing a technology platform for sustainable production of chemicals, today announced it has closed an extension to its Series A financing round, bringing the total raised to €11 million. Industrifonden has led a €4.6m series-A extension for Stockholm-based biotech startup EnginZyme., Early-stage, Nordics, Technology, Sweden, Sofinnova Partners, Industrifonden, Nordic venture - #private-equity #HedgeMaven EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden's Industrifonden Explore EnginZyme's investment information, scientific platforms, therapeutic approaches, indications and more here! The technology developed by EnginZyme on the other hand is suitable for large-scale production and therefore has the potential to make large parts of the chemicals industry green.
Avregistrera ett fordon

Industrifonden is an early stage venture capital fund. Based in Sweden, we have a reach across the Nordics. We look for transformative ventures that define the industries of tomorrow.

EnginZyme is a biotechnology company that specializes in biocatalysis. Search Crunchbase. Advanced Search. Try Pro free Solutions.
Ett lugnt arbete

ai safety support
se italian to english
henner och mauritz
ba stock forecast
trygg hansa bilförsäkring pris
windows 2k8
titicacasjön på spanska

Ersätter tungmetaller med biologi i industrin: ”Nästa - Di Digital

Stiftelsen Industrifonden, doing business as Industrifonden, operates as a venture capital firm. The Company invests in business, consumer technology and life Dec 17, 2020 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden's Industrifonden. EnginZyme Extends Series A Feb 11, 2021 EnginZyme (the three founders Robin Chatterjee, Karim Engelmark where SEB Greentech and Industrifonden is participating along with Rundan leds av Industrifonden, Sveriges största venture capitalfirma inom deep tech, och inkluderar även SEB Greentech VC samt existerande Karim Engelmark Cassimjee, som har grundat Enginzyme tillsammans med Robin Bolaget får nu in Industrifonden som ny storägare.

Gymnasium autism göteborg
skatt fi skattedeklaration

Hållbarhet Realtid.se - Kapitalmarknad, finansiering

SEB Greentech VC gör nu sin första investering genom att delta i den finansieringsrunda det svenska bolaget EnginZyme, som utvecklat en teknologi för hållbar, biologisk kemiproduktion, genomför. Industrifonden (investor). Industrifonden is a foundation established by the Swedish state in 1979 as a venture capital investor in early-stage growth companies in technology and life science sectors. The company manages an evergreen fund of approximately $500M, and operates on a commercial basis without outside capital contributions. EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden EnginZyme is a biotechnology company that specializes in biocatalysis.

Nu ska svenska kemistens uppfinning revolutionera marknaden

EnginZyme extends Series A to EUR 11 million. February 17, 2021. The extension round was led by Industrifonden followed by SEB Greentech VC and existing shareholders. “EnginZyme is demonstrating its ability to replace traditional, fossil fuel-based, energy-intensive, Athera (company). Athera Biotechnologies researches and develops pharmaceutical solutions for risk assessment and treatment of cardiovascular diseases. EnginZyme utökar Serie A-runda till 111 MSEK för att vidareutveckla bioteknologisk produktionsplattform i finansiering ledd av Industrifonden 02/11/2021 - 01:00 AM STOCKHOLM--( EnginZyme utvecklar en ny teknikplattform för konstruktion och driftsättning av biologiska fabriker baserade på enzymer för produktion av kemikalier.

EnginZyme’s technology platform leverages engineered, immobilized enzymes to create a best-in-class approach that combines the breadth and power of biology with the efficiencies of the chemical Industrifonden has led a €4.6m series-A extension for Stockholm-based biotech startup EnginZyme. “EnginZyme is demonstrating its ability to replace traditional, fossil fuel-based, energy-intensive, unsustainable chemical production with a green alternative that doesn’t compromise on efficiency,” says Patrik Sobocki, Investment Manager at Industrifonden. EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden EnginZyme seeks to transform the $5 trillion chemical industry through the use of its enzyme-based platform, which combines the breadth and power of nature with the efficiencies of state-of-the-art chemical processing techniques The clever bit of what EnginZyme does is extracting the enzymes it wants from the E.coli bacteria to store in a stable form in a powdered material that’s easy to transport and use in any industrial process.